According to Argentum, the agreement generally provides that Argentum may commence marketing its generic equivalent product sometime prior to the expiration of the patents covering Restasis.
In fact, J&J stated is now including the estimated impact of the Actelion transaction in its financial guidance.
Tecentriq (atezolizumab) was granted accelerated approval for the treatment of people with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.
State senators voted 22-9 in favor of approving a measure intended to help ease the state’s growing opioid epidemic.
Tardive dyskinesia is a neurological disorder characterized by repetitive involuntary movements, usually of the jaw, lips and tongue, such as grimacing, sticking out the tongue and smacking the lips.
Company hopes to raise up to $100 million and list on the New York Stock Exchange under the ticker symbol BHVN.
Multiple news outlets state company could receive $2 billion in proceeds for the company it acquired from Merck KGaA’s Merck Serono in 2010.
Specialty pharmaceutical company could be acquired by Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA.
Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) treat the virus in children ages 12 to 17.
The company is targeting front store, retail pharmacy and specialty operations, including rolling out beer and wine and committing to a major upgrade in its cosmetics assortment.